We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
Abbott Diagnostics- Hematology Division

Download Mobile App


ATTENTION: Due to the COVID-19 PANDEMIC, many events are being rescheduled for a later date, converted into virtual venues, or altogether cancelled. Please check with the event organizer or website prior to planning for any forthcoming event.

Biomarkers Predict Long-Term Kidney Function After Acute Kidney Injury

By LabMedica International staff writers
Posted on 27 Oct 2021
Print article
Image: Plasma biomarkers measured three months after hospitalization demonstrate utility in assessing AKI patients for long-term CKD risk (Photo courtesy of National Kidney Foundation)
Image: Plasma biomarkers measured three months after hospitalization demonstrate utility in assessing AKI patients for long-term CKD risk (Photo courtesy of National Kidney Foundation)
Acute kidney injury (AKI), previously called acute renal failure (ARF), is a sudden decrease in kidney function that develops within seven days, as shown by an increase in serum creatinine or a decrease in urine output, or both.

AKI may lead to a number of complications, including metabolic acidosis, high potassium levels, uremia, changes in body fluid balance, and effects on other organ systems, including death. People who have experienced AKI are at increased risk of developing chronic kidney disease in the future.

Medical Scientists at the Royal Derby Hospital (Derby, UK) and their colleagues evaluated a number of new blood tests in people who have had AKI, aiming to improve the ability to assess the risk of new or progressive kidney disease. Among a panel of 11 biomarkers tested, a combination of the most promising were identified, comprising Soluble Tumor Necrosis Factor Receptor (sTNFR)1, sTNFR2, cystatin C and eGFR. A total of 500 patients were studied that included adults from a single clinical center who developed AKI, and survived until three years after the hospitalization during which AKI occurred. Participants included those with and without pre-existing chronic kidney diseases (CKD).

The investigators reported that soluble tumor necrosis factor receptor 1 (sTNFR1), sTNFR2, cystatin C, neutrophil gelatinase-associated lipocalin (NGAL), three-month eGFR and urine albumin:creatinine ratio (ACR) were independently associated with kidney disease progression and were more important than AKI severity or duration. A multivariable model containing sTNFR1, sTNFR2, cystatin C and eGFR discriminated between those with and without kidney disease progression (AUC 0.79, 95% CI 0.7-0.83). Optimizing the cut-point to maximize utility as a ‘rule-out’ test to identify those at low risk increased the sensitivity of the model to 95% and its negative predictive value to 92%.

The authors concluded that a panel of plasma biomarkers measured 3-months after discharge from a hospitalization complicated by AKI provides potential opportunity to identify patients who are at very low risk of incident or worsening CKD. Further study is required to determine its clinical utility through independent prospective validation. The study was published on October 12, 2021 in the American Journal of Kidney Diseases.

Related Links:
Royal Derby Hospital

Gold Supplier
Lactate Dehydrogenase (LDH) Assay
Mobile Clinical Chemistry Lab
Statlab Station
Silver Supplier
Immunoassay Reader
VEGA-200 Reader
Mechanical Pipette
Accumax Smart

Print article


Molecular Diagnostics

view channel
Image: The TruSight RNA Fusion Panel kit provides comprehensive gene fusion detection in formalin-fixed, paraffin-embedded (FFPE) and other cancer samples (Photo courtesy of Illumina)

Targeted RNA-Sequencing Panel Detects Gene Fusions in Solid Tumors

Increasingly, rearrangements resulting in gene fusions have been revealed in multiple tumor types across diverse organ systems. These gene fusions can drive tumorigenesis by altering gene expression and activity.... Read more


view channel
Image: Blood smear from a patient with low grade follicular lymphoma in leukemic phase: note cleaved nuclei (coffee bean cells) and scant cytoplasm (Photo courtesy of Kyle Bradley, MD)

Classification of Mature B-Cell Neoplasms Employing Standardized Flow Cytometry

The classification of lymphoid neoplasms integrates clinical, pathological, immunophenotypic, genetic, and molecular data in order to distinguish between mature B-cell lymphoma entities.... Read more


view channel
Image: Procartaplex Immunoassays Kits are based on the principles of a sandwich ELISA, using two highly specific antibodies binding to different epitopes of one protein to quantitate all protein targets simultaneously (Photo courtesy of Thermo Fisher Scientific)

Assay Developed for Patient-Specific Monitoring and Treatment for Ovarian Cancer

Tumors can influence peripheral immune macroenvironment, thereby creating opportunities for non-invasive serum/plasma immunobiomarkers for immunostratification and immunotherapy designing.... Read more


view channel

Roche Introduces AI-Based Digital Pathology RUO Algorithms for Evaluation of Breast Cancer Markers

Roche (Basel, Switzerland) has announced the research use only (RUO) launch of three new automated digital pathology algorithms, uPath Ki-67 (30-9), uPath ER (SP1) and uPath PR (1E2) image analysis for... Read more


view channel
Image: PKeye Workflow Monitor System (Photo courtesy of PerkinElmer, Inc.)

PerkinElmer’s New Cloud-Based Platform Enables Laboratory Personnel to Remotely Manage Its Instruments in Real-Time

PerkinElmer, Inc. (Waltham, MA; USA) has launched its PKeye Workflow Monitor, a cloud-based platform enabling laboratory personnel to remotely manage and monitor their PerkinElmer instruments and workflows... Read more


view channel

Global Point-of-Care Coagulation Testing Market to Be Driven by Growing Geriatric Population

The global point-of-care (POC) coagulation testing market is set to achieve significant growth on the back of the growing geriatric population and increasing technological innovations in POC testing, although... Read more
Copyright © 2000-2021 Globetech Media. All rights reserved.